The Health Care Investor
Baxter Delays PharMEDium Acquisition After Meningitis Outbreak
Baxter International has placed its acquisition of PharMEDium Healthcare Corp. on hold following the nationwide meningitis outbreak, according to LBO Wire, a part of Dow Jones.
The outbreak has been tied by the Centers for Disease Control and Prevention and the Food and Drug Administration to New England Compounding Center.
While PharMEDium, which is backed by Oak Investment Partners and Baird Private Equity, has not been linked to any of the meningitis cases, the outbreak created enough uncertainty concerning the safety of compounding companies to delay Baxter's planned acquisition, according to a Crain's report.
Trackbacks (0)
Links to blogs that reference this article
Trackback URL
http://www.thehealthcareinvestor.com/admin/trackback/288223
http://www.thehealthcareinvestor.com/admin/trackback/288223
Comments (0)
Read through and enter the discussion with the form at the end
McGuireWoods LLP
|
One James Center
|
Richmond,
VA
23219
804-775-1000
|